

Recent Increase in Fluconazole-Nonsusceptible *Candida parapsilosis* in a Global Surveillance with the Expansion of the Erg11 Y132F genotype and a Rapid Detection Method to Detect This Alteration

Cory M. Hubler, Cecilia G. Carvalhaes, Mariana Castanheira
JMI Laboratories, North Liberty, Iowa, US

Objective

- We evaluated the rates of fluconazole-nonsusceptible *C. parapsilosis* among isolates from 2018 to 2021.
- Additionally, we developed a PCR assay for the rapid detection of the Y132F Erg11 alteration in *C. parapsilosis*.

Conclusions

- Fluconazole-nonsusceptible *C. parapsilosis* rates increased from 10.2% in 2018 to 15.4% in 2021.
- These isolates were detected in 12 of 30 surveyed countries.
- The highest rates of Erg11 Y132F were observed in Europe (92.7%), followed by the US (60.9%).
- The Y132F Erg11 alteration was detected in 83.2% of the isolates (104/125) collected during 2018–2021 by the designed PCR method.
- Y132F Erg11-positive isolates were mostly resistant to voriconazole, but posaconazole and itraconazole MIC values were all wildtype.
-